关于我们

Founded in 2018, China Immunotech (Beijing)Biotechnology Co., LTD is dedicated to biopharmaceutics research and development. The founder and leading scientist, Dr. Xin Lin is a full-time tenured chair professor of Tsinghua University in Beijing,China. The core technology team is composed of postdoctoral fellows and PhD researchers from top universities and institutes, with high-level expertise in biology, immunology and biomedical research. 

image.png

                                                                                                                   Company founder: Dr. Xin Lin


Professor Xin Lin is the dean and tenured chair professor of School of Medicine, Tsinghua University. He is endowed as the chair professor of "Yangtze River Scholar" of Ministry of Education, national expert of "Thousand Persons Program", visiting professor of Peking University People's Hospital, deputy director of Beijing Engineering Laboratory of Cell Therapy, and director for the Joint Hematologic Malignancies Research Center of Tsinghua University Hospital and Beijing Ludaopei Hematology Research Institute.  In 2014, He moved back to China and joined the Tsinghua University. 


Professor Xin Lin has been devoted to T cell activation-related immunological research for over 20 years. He was the first in the world to discovery the key molecule CARMA1 in TCR signaling pathway, and did a comprehensive research of the T cell response signaling network. He has over 100 publications and his major discovery is documented into Janeway’s Immunobiology, the most classic textbook in the immunology research field. And he also undertook several national-funded projects after he moved back to China. 


Professor Xin Lin and his research team also put many efforts in translational research, mainly focused on the development and application of immunotherapy to treat a variety of human cancers. Their research team has been developing novel TCR-T cell, CAR-T cell and the original patented STAR-T cell therapy; and also establishing the platform for tumor-neoantigen characterization and tumor neoantigen-based personalized medicine.


Approach and Platform


 We mainly focus on developing cell-based immunotherapies against a variety of diseases, including the cutting-edged Chimeric Antigen Receptor T (CAR-T) cell therapy and the engineered T Cell Receptor T (TCR-T) cell therapy. We have established full-scaled research pipeline for TCR-T and CAR-T cells to target hematologic malignancies, solid tumors and virus infection-related diseases.


We have set up several leading technology research platforms. The TCR-T cell platform includes the following key techniques: tetramer manufacture, specific TCR screening and selection, TCR-T cells construction, virus preparation and purification, and functional evaluation systems both in vitro and in vivo. The CAR-T cell platform includes the following technologies: single-chained antibody screening and verification, CAR construction and optimization, and the functional assessment systems both in vitro and in vivo.


With the world booming development of biomedical enterprise and the innovative environment under China medical and health system reform, our company will dedicate to develop novel cellular immunotherapy and promote its industrialization. Boosted by the great advance of gene sequencing and big-data technology, our company will explore and develop innovative, personalized immunotherapies to benefit more people.